 SAN DIEGO, Aug. 02, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento today announced that the FDA has authorized Sorrentos IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor DAR - T Cell therapy for relapsed or refractory multiple myeloma. The proprietary CD38 DAR-T cell therapy candidate demonstrated strong cytotoxic activity in preclinical studies. DAR-T product candidates are produced using Sorrentos proprietary, non-viral knockout-knockin KOKI technology, which potentially allows for improved specificity, stability and potency, and enables an off-the-shelf treatment approach, thereby eliminating the need for patients to undergo leukapheresis and undesirable treatment delays to perform cell harvesting, manufacturing and release prior to treatment for each individual cancer patient. 